Life Sciences 2020: The Future is Here

Genomics As of year-end 2018, the North American genomics market was valued at nearly $7.0 billion, with the U.S. accounting for that majority 4 . Direct-to-customer genomic and ancestry services have been a fast-growing subsector with companies such as 23andMe and ancestry.com leading the way. The personalization of care resulting from genomic information is also growing. Stanford Healthcare’s Clinical Genomics Program utilizes genomic information to develop tailored treatments for patients suffering from chronic illness. Cell and Gene Therapy The North American cell and gene therapy market—also dominated by the U.S.—holds the largest global market share of the sector and is forecast to grow 33.8% at a compound annual growth rate, (CAGR) through 2026. While gene therapy is not available for widespread use yet, current research could have an immense payoff in terms of new treatments. Clinical trials have yielded some promising results in oncology, and the U.S. Food and Drug Administration (FDA) has approved the sale of a limited number of gene therapy products.

Gene Editing Gene-based therapies aim to treat disease by adding, removing or altering genetic material at the DNA level. Applications of these technologies are not limited to human disease; they can also be utilized in agriculture to improve the food supply, and in animal genetic engineering. These include CRISPR and CAR-T-Cell Therapy. Artificial Intelligence (AI) in Life Sciences Artificial intelligence (AI) is captivating markets around the world and its applications in various sectors are poised to disrupt and transform. From accelerating drug development to transforming diagnostics, AI technology is primed to speed up the pace of life sciences innovations, which are already running at a breakneck pace. While gene therapy is not available for widespread use yet, current research could have an immense payoff in terms of new treatments.

4 Fortune Business Insights

6 / CUSHMAN & WAKEFIELD